Syndax Pharmaceuticals said Tuesday that its genetically targeted cancer drug induced complete remissions in patients with advanced leukemia, although questions may linger about a heart-related side effect that limited dosing.
The Syndax drug, a once-daily pill called SNDX-5613, belongs to an emerging class of so-called menin inhibitors that have the potential to become effective treatments for certain types of genetically defined leukemia that do not respond well to currently approved medicines. These drugs work by blocking the interaction of two proteins that prevents bone marrow cells from developing or differentiating into healthy cells.
Based on the new results, Syndax intends to push SNDX-5613 into an expanded Phase 2 study later this quarter. If positive, the enlarged study would provide the data necessary to seek marketing approvals.
Was the market expecting a different outcome?
Comments are closed.